Viva Biotech Holdings (HKSE:01873) Debt-to-Equity : 0.52 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Debt-to-Equity?

Viva Biotech Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,042 Mil. Viva Biotech Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,040 Mil. Viva Biotech Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$4,034 Mil. Viva Biotech Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.52.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Viva Biotech Holdings's Debt-to-Equity or its related term are showing as below:

HKSE:01873' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.31 Max: 0.79
Current: 0.52

During the past 8 years, the highest Debt-to-Equity Ratio of Viva Biotech Holdings was 0.79. The lowest was 0.01. And the median was 0.31.

HKSE:01873's Debt-to-Equity is ranked worse than
74.86% of 1066 companies
in the Biotechnology industry
Industry Median: 0.15 vs HKSE:01873: 0.52

Viva Biotech Holdings Debt-to-Equity Historical Data

The historical data trend for Viva Biotech Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings Debt-to-Equity Chart

Viva Biotech Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.79

0.68

0.78

0.52

Viva Biotech Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial									0.68	0.72	0.78	0.80	0.52

Competitive Comparison of Viva Biotech Holdings's Debt-to-Equity

For the Biotechnology subindustry, Viva Biotech Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viva Biotech Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's Debt-to-Equity falls into.

Viva Biotech Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Viva Biotech Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1041.76	+	1039.939)	/	4033.76
	=	0.52

Viva Biotech Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1041.76	+	1039.939)	/	4033.76
	=	0.52

Viva Biotech Holdings (HKSE:01873) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Viva Biotech Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Viva Biotech Holdings (HKSE:01873) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

VBIZF:USA VB0:Germany

Address

735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318

Website

https://www.vivabiotech.com

Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation ("CDMO") and commercialisation services segment includes contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations.

Executives

Mao Chen Cheney	2101 Beneficial owner
Wu John Jiong	2201 Interest of corporation controlled by you
Fenghe Harvest Ltd	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Mao Jun	2501 Other
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Zhou Min	2202 Interest of your spouse
Intertrust (singapore) Ltd.	2301 Trustee
Z&m International Holdings Limited	2201 Interest of corporation controlled by you
Zhang And Sons Limited	2101 Beneficial owner

Viva Biotech Holdings (HKSE:01873) Headlines

No Headlines